Tags

Type your tag names separated by a space and hit enter

Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
J Med Virol. 2006 Dec; 78(12):1509-12.JM

Abstract

Severe acute respiratory syndrome (SARS)-coronavirus (SARS-CoV) is the causative agent of SARS. The S protein of SARS-CoV is a major target for neutralizing antibodies (Nabs) in infected patients. We developed a neutralization assay using a recombinant vesicular stomatitis virus (VSV) bearing SARS-CoV-S protein (VSV-SARS-St19). A total of 56 serum samples collected from 22 healthcare workers in the Hanoi French Hospital during the SARS epidemic in 2003 were evaluated and compared to the conventional neutralizing assay using infectious SARS-CoV. The results of the neutralization assay using VSV-SARS-St19 pseudotype showed good correlations with those using infectious SARS-CoV. The newly developed neutralization assay was more sensitive to low antibody titers in serum samples. Thus, the VSV-SARS-St19 is a useful tool for detecting Nabs against SARS-CoV.

Authors+Show Affiliations

Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan. fukushi@nih.go.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17063504

Citation

Fukushi, Shuetsu, et al. "Evaluation of a Novel Vesicular Stomatitis Virus Pseudotype-based Assay for Detection of Neutralizing Antibody Responses to SARS-CoV." Journal of Medical Virology, vol. 78, no. 12, 2006, pp. 1509-12.
Fukushi S, Mizutani T, Saijo M, et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J Med Virol. 2006;78(12):1509-12.
Fukushi, S., Mizutani, T., Saijo, M., Kurane, I., Taguchi, F., Tashiro, M., & Morikawa, S. (2006). Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. Journal of Medical Virology, 78(12), 1509-12.
Fukushi S, et al. Evaluation of a Novel Vesicular Stomatitis Virus Pseudotype-based Assay for Detection of Neutralizing Antibody Responses to SARS-CoV. J Med Virol. 2006;78(12):1509-12. PubMed PMID: 17063504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. AU - Fukushi,Shuetsu, AU - Mizutani,Tetsuya, AU - Saijo,Masayuki, AU - Kurane,Ichiro, AU - Taguchi,Fumihiro, AU - Tashiro,Masato, AU - Morikawa,Shigeru, PY - 2006/10/26/pubmed PY - 2007/1/11/medline PY - 2006/10/26/entrez SP - 1509 EP - 12 JF - Journal of medical virology JO - J Med Virol VL - 78 IS - 12 N2 - Severe acute respiratory syndrome (SARS)-coronavirus (SARS-CoV) is the causative agent of SARS. The S protein of SARS-CoV is a major target for neutralizing antibodies (Nabs) in infected patients. We developed a neutralization assay using a recombinant vesicular stomatitis virus (VSV) bearing SARS-CoV-S protein (VSV-SARS-St19). A total of 56 serum samples collected from 22 healthcare workers in the Hanoi French Hospital during the SARS epidemic in 2003 were evaluated and compared to the conventional neutralizing assay using infectious SARS-CoV. The results of the neutralization assay using VSV-SARS-St19 pseudotype showed good correlations with those using infectious SARS-CoV. The newly developed neutralization assay was more sensitive to low antibody titers in serum samples. Thus, the VSV-SARS-St19 is a useful tool for detecting Nabs against SARS-CoV. SN - 0146-6615 UR - https://www.unboundmedicine.com/medline/citation/17063504/Evaluation_of_a_novel_vesicular_stomatitis_virus_pseudotype_based_assay_for_detection_of_neutralizing_antibody_responses_to_SARS_CoV_ L2 - https://doi.org/10.1002/jmv.20732 DB - PRIME DP - Unbound Medicine ER -